Business Context and Reporting Period
This Form 8-K Current Report was filed by Caribou Biosciences, Inc. on May 12, 2022. The filing primarily discloses positive initial clinical data from the ongoing ANTLER Phase 1 clinical trial for the Company's allogeneic anti-CD19 CAR-T cell therapy product candidate, CB-010, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
Key Financial Metrics
This filing is a current report regarding clinical trial updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Clinical Data
The filing details the publication of an abstract by the European Hematology Association (EHA) containing initial data from the ANTLER Phase 1 trial. Key clinical findings as of the February 23, 2022 data cutoff include:
- Efficacy: Among five patients evaluable for efficacy, all achieved a response (100% overall response rate) at 28 days following a single dose of 40 million CAR-T cells. Four out of five (80%) responding patients achieved a complete response (CR).
- Durability: All four patients who achieved a CR at 28 days maintained an ongoing CR at three months. The longest measured CR was at six months, though one patient relapsed at the six-month evaluation.
- Safety: No cases of graft-versus-host disease were observed. Adverse events included neutropenia (3/6), thrombocytopenia (2/6), anemia (1/6), and hypogammaglobulinemia (1/6). One patient experienced Grade 1 cytokine release syndrome and Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), which resolved with supportive care.
- Progression: Based on this profile, the trial is enrolling patients in cohort two at a higher dose level (80 million CAR-T cells).
Outlook, Risks, and Management Commentary
Management plans to present additional data, including longer follow-up on cohort one patients, at the EHA 2022 Hybrid Congress in Vienna, Austria, from June 9-17, 2022. The Company intends to release further clinical data from the ANTLER trial by year-end.
Risks and Contingencies:
- Interim Data Limitations: The data is based on a limited number of patients (six total) and a specific cutoff date. Initial or interim data may not be predictive of final safety and efficacy.
- Relapse Risk: One patient who achieved a complete response relapsed at the six-month evaluation. Further data may reveal additional relapses or adverse results.
- Future Uncertainty: The Company makes no representation regarding whether future data will support or contradict the initial findings.
Investor Verification Checklist
- Verify the full text of the EHA abstract and the press release (Exhibit 99.1) for complete safety and efficacy tables.
- Monitor the presentation at the EHA 2022 Hybrid Congress (June 2022) for updated data extending beyond the February 23, 2022 cutoff.
- Review the Company's most recent Form 10-K for comprehensive risk factors regarding clinical trials and financial status.
- Track enrollment progress in cohort two (80 million CAR-T cells) to assess dose escalation safety.